Clinical trial
Efficacy and Safety Study of Esomeprazole 20mg qd vs Ranitidine 150mg Bid in…
NCT00401752 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00401752 |
|---|---|
| Title | Efficacy and Safety Study of Esomeprazole 20mg qd vs Ranitidine 150mg Bid in Patients With an NSAID-induced Gastric Ulcer |
| Official title | A Multicenter, Randomized, Double-blind, Double-dummy, Parallel-group, 8 Week Comparative Efficacy and Safety Study of Esomeprazole 20 mg Every Day (qd) Versus Ranitidine 150 mg Twice a Day (Bid) in Patients With an NSAID-associated Gastric Ulcer When Daily NSAID is Continued |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Gastric Ulcer |
| Intervention type | Drug |
| Interventions | Esomeprazole, Ranitidine |
| Enrollment | 397 |
| Start date | Mar 1, 2006 |
| Completion | Nov 1, 2008 |
| First posted | Nov 22, 2006 |
| Last update posted | Jul 8, 2010 |
| Countries | China, Hong Kong |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: